Alexion Pharmaceuticals (ALXN) 10-Q2013 Q1 Quarterly report

Filed: 30 Apr 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: addressing, Advisory, analyzing, bankruptcy, BLA, bribery, broader, bulk, cGMP, collateral, constitutionality, consulting, decree, detail, detaining, deviating, DGF, disagreement, disapproval, endorse, epidemiologic, Excellence, experimentation, fit, floating, Good, graft, HTA, immunological, inappropriate, ineligibility, infant, injury, introduce, introduced, IRB, ISSUER, jurisdictional, Kingdom, maximum, NICE, noncompliance, penalized, pending, pertaining, pivotal, PPACA, procedure, programme, proportion, protocol, reclassification, redundancy, registration, Relief, resolve, resolving, respond, responded, satisfactorily, save, seizing, sequester, site, SmPC, societal, Specialised, spread, strictly, Supreme, suspension, synthetic, Taxpayer, threat, undertaken, unrecognized, UNREGISTERED, untitled, upheld

Removed: abandonment, ABO, accompanied, adjusted, advancing, allocation, America, amortized, annum, approach, approximate, assigned, assumed, assured, bad, bear, Cambridge, Canada, cancer, Chase, CLL, cofactor, collected, combined, commonly, consecutive, creditworthy, dated, DDD, deductible, deemed, delivery, depending, destroy, determinable, doubtful, encoding, enrolled, enrolling, Escherichia, execution, expressing, extend, Fenner, fixed, forma, gene, hypophosphatasia, immunosuppressant, incremental, IND, indemnification, index, inorganic, institution, integrate, integrated, investigational, joint, JPMorgan, leukemia, leverage, LLC, lymphocytic, Lynch, macular, Maine, maturity, Merrill, million, minimal, mismatch, modulate, molybdenum, Montreal, Morgan, myeloma, nephropathy, nephrotic, network, noncurrent, Nonspecific, objective, occupancy, older, onset, paper, participant, passed, payor, persuasive, pharmacy, Pierce, pipeline, point, portfolio, privately, pro, processing, produced, prosecuted, protein, proteinuria, pyridoxal, rarely, ratio, RBS, recipient, reconciliation, regular, regulator, reimburse, remitted, representative, representing, restated, samalizumab, sensitized, settled, simultaneously, Smith, Society, source, statutorily, strength, suffering, Suntrust, surface, survive, syndication, thereto, title, variation, VAT

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ALXN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended March 31, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Leonard Bell, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated:	April 30, 2013	/s/ LEONARD BELL, M.D.
		Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.